Eiger BioPharmaceuticals Other Current Liabilities

As of the most recent data (December 2023), EIGR shows a other current liabilities of $10M. That compares with $16M in the prior-year period — down 36.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, EIGR's other current liabilities is now $10M (was $16M) — a 36.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Eiger BioPharmaceuticals is outperforming or lagging.

Tracking EIGR's other current liabilities over time shows whether Eiger BioPharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $10M That compares with $16M in the prior-year period — down 36.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current liabilities page, Stockcircle has Eiger BioPharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $10M) with ownership activity and broader fundamentals.

Eiger BioPharmaceuticals's other current liabilities is $10M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.